APPLICATIONS PUBLISHED 2 MAY 2002
Published: 1-Nov-2002
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Stable hydrogenated lupulone anti-bacterial oral compsns
Colgate-Palmolive 1200053*
A process for stabilising antioxidant compsns, and aqueous compsns
Industria E Comercio de Cosmeticos Natura 1200056*
Delivery system for oral care compsns comprising organosiloxane resins using a removable backing strip
Procter & Gamble 1200064*
Intravaginal clindamycin ovule compsn
Pharmacia & Upjohn 1200065*
Aqueous nasal formulation
Glaxo Wellcome KK 1200066*
Delivery system for biological material
Hilgers, Arnold 1200067*
Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
The Stehlin Foundation for Cancer Research 1200068*
A binder for pharmaceutical compsns
CTS Chemical Industries 1200069*
Ambroxol-containing lozenge
Boehringer Ingelheim International 1200070*
Low-dose tablets and preparation method
Laboratoires des Produits Ethiques Ethypharm 1200071*
Method of treating psychotic disorders
Solvay Pharmaceuticals 1200072*
Use of diphenyliodonium for the activation and protection of cytotoxic lymphocytes
Maxim Pharmaceuticals 1200074*
Nutrient formulation for disease reduction, and related treatment and component screening methods
Nutri-Logics 1200075*
Calcilytic compounds
SmithKline Beecham 1200076*
L-acetylcarnitine and L-propionylcarnitine containing compsn for the prevention and treatment of kidney disfunctions and diseases
Sigma-Tau Healthcare 1200077*
Compsns and methods for promoting nerve regeneration
Oregon Health and Science University 1200078*
2-aminotetralin derivatives for the therapy of glaucoma
Chiesi Farmaceutici 1200079*
Assay for D-serine transport antagonist and use for treating psychosis
Javitt, Daniel 1200080*
Preparations for reducing oxygen consumption during physical efforts
Wiss, Oswald 1200082*
Antibiotic compound
Merck 1200083*
Use of an angiotensin II type 1 receptor antagonist in the manufacture of a medicament for the treatment of cardiovascular complications
AstraZeneca 1200084*
Pharmaceutical and nutritional compsns containing essential fatty acids and homocysteine-lowering agents
Laxdale 1200085*
Methods for treating or preventing pain and anxiety
Icagen 1200086*
Nociceptin receptor ORL-1 agonists for use in treating cough
Schering 1200087*
Paracetamol and drotaverine containing compsn
Chinoin Gy²gyszer es Vegyeszeti Termekek Gyara 1200088*
Pyridimomorphinans and use thereof
Southern Research Institute 1200089*
Beta-carboline pharmaceutical compsn
Lilly Icos 1200090*
Beta-carboline drug products
Lilly Icos 1200092*
Ophthalmic compsns containing antibiotics and NSAIDS
Allergan Sales 1200094*
Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances
Solvay Pharmaceuticals 1200095*
Tixocortol pivalate suspension, mouth-wash based thereon and packaging containing same
Warner-Lambert Company 1200096*
Method for controlling the fidelity and the execution of reverse transcriptase by incorporating and polymerising nucleotide analogues accepted as substrates of the reverse transcription response without blocking its elongation
Centre National de la Recherche Scientifique 1200097*
Combined preparations comprising daunorubicin derivatives and anti-HER2 antibodies
Pharmacia Italia 1200098*
Synergistic compsn comprising daunorubicin derivatives and antimetabolite compounds
Pharmacia Italia 1200099*
Use of rhamnolipids in wound healing, treatment, and prevention of gum disease and periodontal regeneration
Stipcevic, Tamara; Piljac, Tihana; Piljac, Jasenka; Dujimic, Tatjana; Piljac, Goran 1200100*
Methods for treating autoimmune diseases
Supergen 1200102*
Xenon as NMDA antagonist
Imperial College of Science, Technology and Medicine 1200103*
Cadmium-containing compsns
Cancer2 1200104*
Modified factor VIII
Emory University 1200105*
Compsn containing extracts of Butyrospermum parkii and the use as a medicament or dietary supplement
Astion Development 1200106*
Compsn having steroidal estrogen effect without increasing the risk of breast cancer
Kobenhavns Universiteit 1200107*
Use of gingko extract
Societe de Conseils de Recherches et d'Applications Scientifiques 1200108*
Inducing cellular immune responses to hepatitis C virus using peptide and nucleic acid compsns
Epimmune 1200109*
In vivo induction for enhanced function of isolated hepatocytes
Organogenesis 1200110*
Compsns for the treatment of the catabolic state of prolonged critical illnesses
Novo Nordisk 1200111*
Chemokine bonding of gammaherpesvirus 68 and methods of use therefor
Cambridge University Technical Services; Efstathiou, Stacey; Alcami, Antonia; Parry, Christopher Marc 1200112*
Reagents and methods useful for detecting diseases of the prostate
Abbott Laboratories 1200113*
PPAR delta inhibitors for the treatment of cardiovascular diseases
The University of Dundee 1200114*
Multi-dose erythropoietin formulations
Aventis Pharma 1200115*
Use of FVIIA or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
Novo Nordisk 1200116*
Lipoprotein lipase (LPL) variant therapeutics
The University of British Columbia; Amsterdam Molecular Therapeutics; Academic Hospital at the University of Amsterdam 1200117*
A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug
AstraZeneca 1200118*
